Jason Hoitt
Corporate Officer/Principal bei STOKE THERAPEUTICS, INC.
Aktive Positionen von Jason Hoitt
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
STOKE THERAPEUTICS, INC. | Corporate Officer/Principal | 15.04.2024 | - |
Karriereverlauf von Jason Hoitt
Ehemalige bekannte Positionen von Jason Hoitt
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
PROVENTION BIO, INC. | Corporate Officer/Principal | 01.06.2020 | 01.06.2023 |
DOVA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 16.12.2018 | 12.11.2019 |
INSMED INCORPORATED | Vertrieb & Marketing | 01.05.2017 | - |
SAREPTA THERAPEUTICS, INC. | Vertrieb & Marketing | 01.01.2013 | 01.05.2017 |
Ausbildung von Jason Hoitt
College of the Holy Cross (Massachusetts) | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
Corporate Officer/Principal | 3 |
Sales & Marketing | 2 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 6 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
INSMED INCORPORATED | Health Technology |
SAREPTA THERAPEUTICS, INC. | Health Technology |
STOKE THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
Provention Bio, Inc.
Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
- Börse
- Insiders
- Jason Hoitt
- Erfahrung